On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September 2024 ruling that Alexion...more
6/19/2025
/ Biotechnology ,
Breach of Contract ,
Clinical Trials ,
Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Damages ,
Life Sciences ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry
On July 9, 2021, the Delaware Court of Chancery (Slights, V.C.) issued an opinion in Bardy Diagnostics, Inc. v. Hill-Rom, Inc., No. 2021-0175-JRS, concluding that the requirements of a “material adverse effect” (“MAE”) clause...more